Sheridan Capital Partners has announced it has invested in Carolina Components Group (CCG).

CCG, founded in 2020 and headquartered in Durham, North Carolina, is a provider of bioprocessing assemblies and components used in the manufacturing of biopharmaceuticals. 

Sheridan, founded in 2012 and based in Chicago, is a healthcare-focused firm that pursues buyouts and growth equity investments in the lower middle market. The firm concentrates on providers, outsourced services, products and manufacturing, and software and technology.

Terms of the investment were not disclosed.

Nordic Capital has entered into a definitive agreement to acquire the medical business of BWX Technologies in a transaction valued at up to $800 million, according to a news release.

BWX Technologies (NYSE: BWXT), based in Lynchburg, Virginia, is a manufacturing and engineering company that provides nuclear solutions for global security, clean energy, environmental restoration, nuclear medicine and space exploration.

Nordic, founded in 1989 and with its U.S. office in New York, is a private equity firm that focuses on healthcare and several other sectors.

The transaction, which is expected to close by the end of 2026, includes BWXT Medical and Kinectrics’ stable medical isotopes business. BWXT will retain a minority ownership in the new company.

KKR has entered into a definitive agreement to acquire Integer Holdings Corp. in a transaction valued at approximately $5.7 billion, according to a news release.

Integer (NYSE: ITGR), founded in 1970 and based in Plano, Texas, is a global medical device contract development and manufacturing organization serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. The company’s brands include Greatbatch Medical and Lake Region Medical.

KKR (NYSE: KKR) is a global investment firm that offers alternative asset management as well as capital markets and insurance solutions.

The transaction is expected to close by the end of the year. Upon its completion, Integer will become a privately held company.

In this episode of the Becker Private Equity & Business Podcast, Holly Buckley, Chair of Healthcare at McGuireWoods, discusses the latest healthcare private equity trends, including transaction volume, physician practice investments, AI adoption, state regulations and the outlook for deals and exits.

Three million children in the U.S. could benefit from Prescribed Pediatric Extended Care (PPEC), but most families don’t know it exists. Jeffrey Soffen, CEO of Spark Pediatrics, the largest PPEC provider in the country, joins McGuireWoods partner Tim Fry on The Corner Series.

Jeff explains how today’s standard of care leaves 40 to 60 percent of skilled nursing hours unfulfilled, forcing medically complex children to remain hospitalized for upward of 500 days. Spark’s model places children in community-based centers for skilled nursing, therapies and peer socialization. Tune in for Jeff’s perspective on state-by-state legislative expansion, health system partnership and why you can do well by doing good in Medicaid.

RS2 Healthcare Partners has invested in KMM Group, according to a news release.

KMM, founded in 2020 and based in Hatboro, Pennsylvania, is a contract manufacturer specializing in components for the medical device industry and other markets.

RS2, founded in 1989 and based in Boston, focuses on healthcare investing in the lower middle market. Formerly Riverside Partners, the firm focuses on pharma services, medical device contract manufacturing and technology-enabled healthcare, among other subsectors. 

Terms of the investment were not disclosed.

SkyKnight Capital has entered into a definitive agreement to invest in Apex Infusion, according to a news release.

Apex, founded in 2006 and headquartered in Signal Hill, California, is an infusion provider that delivers therapies to patients across a network of ambulatory infusion suites and in-home care.

SkyKnight Capital, founded in 2015 and with locations in Burlingame, California and New York, is a private equity firm focused on healthcare and a few other sectors. The firm seeks to invest $25 million to $250 million or higher in companies to acquire 25% to 75% or higher equity ownership.

Apex’s management team will retain a significant ownership stake, and FFL Partners, an existing investor in the company, will remain a minority investor.

Terms of the investment were not disclosed.

Warburg Pincus has announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare from Nautic Partners, General Atlantic and The Vistria Group, supported by a material minority investment from a subsidiary of the Abu Dhabi Investment Authority.

Nautic Partners and PANTHERx management will remain significant shareholders alongside the new investor group, while General Atlantic and The Vistria Group are exiting their positions.

PANTHERx Rare, founded in 2011 and based in Pittsburgh, Pennsylvania, is an independent rare pharmacy.

Warburg Pincus, founded in 1966 and based in New York, is a global private equity firm focused on growth investing. The firm takes a long-term perspective and invests in businesses at all stages of development within healthcare and several other sectors.

Nautic, based in Providence, Rhode Island, is a middle market private equity firm focused on investments in healthcare and a few other sectors. The firm prefers to make $50 million to $500 million-plus equity commitments in a variety of buyout, growth and consolidation opportunities of North American companies, targeting EBITDA of $10 million to $100 million-plus.

General Atlantic, founded in 1980 and based in New York, is a global growth equity firm that prefers to make more substantial investments from a dollars perspective in healthcare and a number of other sectors. The firm pursues healthcare investments in the provider services, life sciences/pharmaceutical industry, hospitals/major facilities and non-reimbursement industries. 

The Vistria Group, founded in 2013 and based in Chicago, focuses on making investments in middle market companies in healthcare and a few other industries. The firm pursues control and minority equity investments and prefers to make more substantial investments from a dollars perspective in companies with at least $100 million in revenue.

Terms of the transaction were not disclosed. Industry reports valued the transaction at more than $7 billion.